Comment
doi: 10.1016/S2468-1253(23)00081-X.
Treatment de-escalation in Crohn's disease - Author's reply
Affiliations
- PMID: 37030300
- DOI: 10.1016/S2468-1253(23)00081-X
Item in Clipboard
Comment
Treatment de-escalation in Crohn's disease - Author's reply
Lancet Gastroenterol Hepatol.
2023 May.
No abstract available
Conflict of interest statement
EL has received educational and research grants from Janssen, Pfizer, AbbVie, Takeda, and Fresenius Kabi; speaker fees from AbbVie, Dr Falk Pharma, Ferring, Janssen, Pfizer, Celgene, Bristol Myers Squibb, Galapagos, and Takeda; advisory board fees for AbbVie, Celgene, Ferring, Janssen, Bristol Myers Squibb, Pfizer, Takeda, Gilead–Galapagos, Arena, and Elli Lilly; and consultancy fees from AbbVie.
Comment on
-
Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial.Lancet Gastroenterol Hepatol. 2023 Mar;8(3):215-227. doi: 10.1016/S2468-1253(22)00385-5. Epub 2023 Jan 11. Lancet Gastroenterol Hepatol. 2023. PMID: 36640794 Free PMC article. Clinical Trial.
-
Treatment de-escalation in Crohn's disease.Lancet Gastroenterol Hepatol. 2023 May;8(5):401. doi: 10.1016/S2468-1253(23)00073-0. Lancet Gastroenterol Hepatol. 2023. PMID: 37030299 No abstract available.